Table of Contents Author Guidelines Submit a Manuscript
Advances in Hematology
Volume 2010, Article ID 268921, 6 pages
http://dx.doi.org/10.1155/2010/268921
Clinical Study

The Effect of Imatinib Mesylate for Newly Diagnosed Philadelphia Chromosome-Positive, Chronic-Phase Myeloid Leukemia in Sub-Saharan African Patients: The Experience of Côte d'Ivoire

Haematology National Teaching Hospital of Abidjan, 21 BP 632, Abidjan 21, Cote D'Ivoire

Received 15 April 2010; Revised 26 May 2010; Accepted 5 July 2010

Academic Editor: Stefan Faderl

Copyright © 2010 K. G. Koffi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. D. Rowley, “A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining,” Nature, vol. 243, no. 5405, pp. 290–293, 1973. View at Google Scholar · View at Scopus
  2. G. Q. Daley, R. A. Van Etten, and D. Baltimore, “Induction of chronic myelogenous leukemia in mice by the P210(bcr/abl) gene of the Philadelphia chromosome,” Science, vol. 247, no. 4944, pp. 824–830, 1990. View at Google Scholar · View at Scopus
  3. M. E. O'Dwyer, M. J. Mauro, and B. J. Druker, “Recent advancements in the treatment of chronic myelogenous leukemia,” Annual Review of Medicine, vol. 53, pp. 369–381, 2002. View at Publisher · View at Google Scholar · View at Scopus
  4. B. J. Druker, M. Talpaz, D. J. Resta et al., “Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia,” New England Journal of Medicine, vol. 344, no. 14, pp. 1031–1037, 2001. View at Publisher · View at Google Scholar · View at Scopus
  5. H. M. Kantarjian, D. Dixon, M. J. Keating et al., “Characteristics of accelerated disease in chronic myelogenous leukemia,” Cancer, vol. 61, no. 7, pp. 1441–1446, 1988. View at Google Scholar · View at Scopus
  6. J. E. Sokal, M. Baccarani, D. Russo, and S. Tura, “Staging and prognosis in chronic myelogenous leukemia,” Seminars in Hematology, vol. 25, no. 1, pp. 49–61, 1988. View at Google Scholar · View at Scopus
  7. A. D. Muheez, O. F. Julius, A. A. Oyekunle et al., “The use of Imatinib mesylate in Nigerians with chronic myeloid leukemia,” Cellular Therapy and Transplantation, vol. 1, no. 2, p. 15, 2008. View at Google Scholar
  8. P. O. Boma, M. A. Durosinmi, I. A. Adediran, N. O. Akinola, and L. Salawu, “Clinical and prognostic features of Nigerians with chronic myeloid leukemia,” The Nigerian postgraduate medical journal, vol. 13, no. 1, pp. 47–52, 2006. View at Google Scholar
  9. C. C. Okany and O. O. Akinyanju, “Chronic leukaemia: an African experience,” Medical Oncology and Tumor Pharmacotherapy, vol. 6, no. 3, pp. 189–194, 1989. View at Google Scholar · View at Scopus
  10. A. F. Fleming and C. Menendez, “Blood,” in Principles of Medicine in Africa, E. Parry, R. Godfrey, D. Mabey, and G. Gill, Eds., vol. 78, Cambridge University Press, Cambridge, UK, 2004. View at Google Scholar
  11. F. D. Groves, M. S. Linet, and S. S. Devesa, “Patterns of occurrence of the leukaemias,” European Journal of Cancer Part A, vol. 31, no. 6, pp. 941–949, 1995. View at Publisher · View at Google Scholar · View at Scopus
  12. H. Kantarjian, C. Sawyers, A. Hochhaus et al., “Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia,” New England Journal of Medicine, vol. 346, no. 9, pp. 645–652, 2002. View at Publisher · View at Google Scholar · View at Scopus
  13. J. E. Sokal, G. A. Gomez, M. Baccarani et al., “Prognostic significance of additional cytogenetic abnormalities at diagnosis of Philadelphia chromosome-positive chronic granulocytic leukemia,” Blood, vol. 72, no. 1, pp. 294–298, 1988. View at Google Scholar · View at Scopus
  14. H. M. Kantarjian, T. L. Smith, and K. B. McCredie, “Chronic myelogenous leukemia: a multivariate analysis of the associations of patient characteristics and therapy with survival,” Blood, vol. 66, no. 6, pp. 1326–1335, 1985. View at Google Scholar · View at Scopus
  15. H. M. Kantarjian, J. E. Cortes, S. O'Brien et al., “Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses,” Blood, vol. 101, no. 1, pp. 97–100, 2003. View at Publisher · View at Google Scholar · View at Scopus
  16. S. G. O'Brien, F. Guilhot, R. A. Larson et al., “Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia,” New England Journal of Medicine, vol. 348, no. 11, pp. 994–1004, 2003. View at Publisher · View at Google Scholar · View at Scopus
  17. H. Kantarjian, M. Talpaz, S. O'Brien et al., “High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia,” Blood, vol. 103, no. 8, pp. 2873–2878, 2004. View at Publisher · View at Google Scholar · View at Scopus
  18. J. Rodriguez, J. Cortes, T. Smith et al., “Determinants of prognosis in late chronic-phase chronic myelogenous leukemia,” Journal of Clinical Oncology, vol. 16, no. 12, pp. 3782–3787, 1998. View at Google Scholar · View at Scopus
  19. S. Sacchi, H. M. Kantarjian, S. O'Brien et al., “Long-term follow-up results of alpha-interferon-based regimens in patients with late chronic phase chronic myelogenous leukemia,” Leukemia, vol. 11, no. 10, pp. 1610–1616, 1997. View at Google Scholar · View at Scopus
  20. H. M. Kantarjian, M. Talpaz, S. O'Brien et al., “Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-α: follow-up results,” Clinical Cancer Research, vol. 8, no. 7, pp. 2177–2187, 2002. View at Google Scholar · View at Scopus
  21. M. W. N. Deininger and B. J. Druker, “Specific targeted therapy of chronic myelogenous leukemia with imatinib,” Pharmacological Reviews, vol. 55, no. 3, pp. 401–423, 2003. View at Publisher · View at Google Scholar · View at Scopus
  22. M. E. Gorre, M. Mohammed, K. Ellwood et al., “Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification,” Science, vol. 293, no. 5531, pp. 876–880, 2001. View at Publisher · View at Google Scholar · View at Scopus
  23. J. Hasford, M. Pfirrmann, R. Hehlmann et al., “A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa,” Journal of the National Cancer Institute, vol. 90, no. 11, pp. 850–858, 1998. View at Google Scholar · View at Scopus
  24. J. E. Sokal, E. B. Cox, and M. Baccarani, “Prognostic discrimination in “good-risk” chronic granulocytic leukemia,” Blood, vol. 63, no. 4, pp. 789–799, 1984. View at Google Scholar · View at Scopus
  25. A. Tolo-Diebkilé, K. G. Koffi, G. D. Sawadogo et al., “Therapeutic Impact of a interferon in chronic myelogenous leukemia,” Mali Medical, vol. 25, no. 1, pp. 22–27, 2010. View at Google Scholar